>I think you have some solid rationale for investing in BSD listed, however I also find it to be part of the problem when investing in anything medical. Like the company, your main focus is on the science and the validity of the product.<
Thanks for the compliment. And thanks for some penetrating observations/questions. However, I disagree with the “problem” you pose – as it is stated, that is. While talk about the science and the effectiveness of the products will not be strongly compelling for, by far, most people in the investment industry, it is all the company could offer, until recently. And, the tech and the medical trials are – absolutely are -- the most important (most predictive) for long-term investors. A serious problem for BSD Medical is the severe weakness in the investment community regarding science, technology, and medical therapy. That is an indictment of that industry, not BSD Medical (or the like).
The above said, things are importantly changed for BSD M.: The many, and necessary, Phase 3 trials for the 2000 series of products are finished or nearing completion, with excellent results. And, the new contracts with distributors, around the world, reflect strongly increased interest in and commitment to BSD Medical’s products; with the MTX-180 being particularly of interest. BSD M. has made very clear this much-improved situation. What more can they do, at this point? Well, they have also made clear that they now think the time is right to do more – and have said they are in fact starting a push for attracting stock analysts, etc. And, the new CFO, William Barth, is clearly leading this push.
>I believe BSD would do well to look outside of the scientific/medical community and hire a person to deal with investor relations. Someone with a proven track record, because I do not believe they are ready for a much higher level of analyst coverage. I will admit they have improved, but they are still amateurish. <
It remains to be seen how well Barth performs – including who, if any, he hires for help. But, the sales levels signed up for in the new contracts will be the main driver of the stock. Right? I want to be ahead of the crowd when that happens!! – even ahead of the actual sales, since those contracts are undoubtedly not frivolous. They were arrived at through careful thought and inquiry by the distributors. The distributors have reacted, very positively, from input by the doctors/hospitals they serve.
>Once the CC was announced, we should have never seen that horrible PR regarding growth of disposable antennas. If that is going to be a measure going forward, I am fine with that... I think many others would be as well, but it should have been explained thoroughly in the CC and defined as a separate metric than previously discussed.
I think they have, in fact, explained he importance of antenna sales. But, I think the reporting of those sales is hampered by the fact that the MTX-180 is still very much in the introductory phase – sales per month can be expected to vary a lot; just like the sales of the large machines. My view is that the new “FPU” marketing plan is working well – by allowing a more-or-less normal acceptance of a new product (but, NOT anything like instant, widespread acceptance – just strong %-age growth).
>Your (Ray) reasons for investing in BSD long term are all true and accurate, they are even good reasons... However, I believe it is a know your audience situation and BSD is not in touch with this crowd. I think the FDA approval is great, I think the machines all work better than anything available, etc... Can they sell? Can they relate that to people that are concerned with financials? I do not believe BSD can until they hire a person who understands the audience and in the stock market, the audience is full of money guys and not scientist. The people who are needed will never understand one tenth of the science behind any of the products... They understand revenue stream, increased sales, zero debt, and sales guaranties... I really hope someone at BSD realizes they need to move from science to business and they get a person(s) with experience to help better convey some of the points the investment community is looking for.<
I’m confident BSD M. is aware of the deplorable status of the investment community. J Not entirely kidding, in that statement -- and BSD Medical cannot change the situation. Only a small percentage of the investment community is tech-savvy enough and, particularly, tech-venture-savvy enough to be wise re such as BSD Medical. However, now, the Phase 3 results for the 2000-series and the overwhelmingly competitive MTX-180 and the new contracts should be sufficiently convincing for even somewhat tech and medical-market savvy people. I expect Barth to be successful in getting BSDM’s potential recognized. That potential is huge, and I think a patient attitude will be hugely rewarded. BSD Medical has developed a safe, very-effective, widely-applicable cancer therapy regimen -- not just another somewhat-effective drug, with horrible side effects, for just one or a few tumors! |
